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ABSTRACT
Introduction: Although insulin products and 
treatment strategies have improved significantly, 
clinical challenges still exist. Meeting glycemic 
goals while minimizing glucose variability and 
hypoglycemia is of utmost importance when 
considering existing insulin therapies and 
designing investigational insulin treatments.
Methods: A PubMed search identified relevant, 
peer-reviewed articles related to the evolution 
of insulin development for this nonsystematic 
review. Search terms included “animal insulin,” 
“synthetic insulin,” “regular human insulin,” 
“insulin lispro,” “insulin aspart,” “insulin 
glulisine,” “insulin glargine,” “insulin detemir,” 
“insulin degludec,” “biphasic human insulin,” 
“insulin premixes,” “ultra-long acting,” “oral 
insulin,” and “inhaled insulin.”
Results: While the discovery of animal insulin 
significantly decreased mortality rates from 
diabetes, issues with availability and large 
variability between batches led to difficulty in 
determining proper doses and, subsequently, 
challenges in achieving glycemic control and 
avoiding hypoglycemia. The development 
of synthetic insulin created a more readily 
available supply, but hypoglycemia still 
persisted. Recombinant DNA technology solved 
insulin production problems and allowed for 
the development of better retarding agents, but 
pharmacokinetic/pharmacodynamic profiles 
still did not mimic natural insulin. Insulin 
premixes offered improved glycemic control, 
decreased intrapatient variability versus self-
mixing, and required fewer injections per day; 
however, patient adherence remained a problem 
due to the need to inject 30–60 minutes before 
a meal for optimal control. This prompted the 
development of rapid-acting insulin analogs 
that could be injected right before a meal and 
long-acting insulin analogs with flatter time-
action profiles.
Conclusion: Despite advances in insulin 
development, a need to provide more 
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these insulins, along with advances in animal 
insulin purification, significantly decreased 
insulin allergy and lipoatrophy. However, these 
preparations did not fully mimic endogenous 
insulin secretion, and hypoglycemia remained 
a common adverse effect [2].
Long-acting (basal) insulin analogs were 
developed to provide a more physiologic 
pharmacokinetic/pharmacodynamic (PK/PD) 
profile with longer duration, less intrapatient 
variability, less pronounced peak in time-action 
profiles, and decreased hypoglycemic risk 
compared with human insulins [3]. Although 
long-acting insulin analogs have improved 
PK/PD profiles and have reduced the safety 
concerns in patients with both type 1 and type 2 
diabetes, up to 40% of patients still require twice-
daily injections of long-acting insulin analogs, as 
the currently available basal insulins do not last 
24 hours in some patients [3–5]. These patients 
in particular could benefit from insulin options 
with longer time-action profiles. In addition 
to long-acting insulin analogs, rapid-acting 
(bolus) insulin analogs were developed to fulfill 
a need for insulin with a faster onset and shorter 
duration than regular human insulin (RHI) [6]. 
Together with long-acting insulin analogs, 
rapid-acting insulin analogs better simulate 
endogenous insulin secretion.
Further enhancements are still necessary 
to ensure optimal insulin treatment. A major 
goal of investigational insulins, including ultra-
long-acting, inhaled, and oral insulins, is to 
provide optimal insulin coverage that more 
closely mimics endogenous insulin secretion, 
while decreasing the risk of hypoglycemia and 
improving adherence. This will ultimately 
improve glycemic control and minimize 
complications. Inhaled and oral insulins also 
represent potential noninvasive routes of insulin 
administration, which could improve patient 
adherence [7–9]. This review will discuss the 
physiologic basal insulin coverage and reduce 
hypoglycemic risk in patients with diabetes 
remains. Newer insulin analogs and more 
convenient routes of insulin delivery have 
shown promising safety and efficacy results. 
Many patients with diabetes have not reached 
glycemic goals on currently available insulins. 
Additional studies are necessary to tailor optimal 
insulin delivery strategies to specific subsets of 
diabetes patients.
Keywords:  Animal insulin;  Diabetes; 
Hypoglycemia; Insulin; Insulin analogs; Regular 
human insulin; Synthetic insulin
INTRODUCTION
Since the breakthrough discovery of insulin 
in 1921, insulin preparation methods and 
treatment strategies have advanced significantly. 
However, clinical challenges regarding the 
management of diabetes with insulin still exist. 
Meeting glycemic goals while minimizing 
glucose variability and hypoglycemia is of 
utmost importance when considering existing 
insulin therapies and designing investigational 
insulin treatments. Insulin products must also 
meet patient lifestyle requirements to help 
increase adherence. For example, it would be 
ideal for all patients on basal insulin to inject 
only once a day.
Although initial preparations of insulin 
from animal sources were successful in treating 
patients with diabetes, these early insulins had 
highly variable efficacy. Impurities in animal 
insulin products were associated with side 
effects such as insulin allergy and lipoatrophy, 
prompting researchers to develop methods for 
insulin purification [1]. Therefore, synthetic 
and recombinant “human” insulins were 
developed to enhance insulin purity as well as 
reproducibility of response. The production of 
592 Adv Ther (2012)  29(7):590–619.
were included and an assessment of the study 
design, methodology, clinical relevance, and 
impact on the evolution of insulin development 
was performed. In addition, the bibliographies 
of articles of interest were reviewed and key 
references were obtained. A total of 92 articles 
was selected and analyzed.
ANIMAL INSULIN
Reduction of Mortality, Adverse Events, and 
Emergence of Hypoglycemia
Before the discovery of insulin, type 1 diabetes 
was a fatal disease due to the inevitable 
development of diabetic ketoacidosis in the 
late stages of the disease process [12]. At that 
time, the goal of treatment was limited to 
reducing mortality, with no caveats to reach 
that goal. Insulin treatment vastly increased the 
life expectancy of patients with diabetes and 
allowed them to meet treatment goals. However, 
glass syringes were used and the needles required 
sharpening before injection. This early insulin 
came from the purification of porcine or bovine 
pancreases [13], and within a few years after 
its discovery, the limitations of animal insulin 
became increasingly apparent. Common adverse 
effects in early insulin treatment included 
insulin allergy, abscesses, lipodystrophy, and 
insulin antibody formation. These adverse effects 
were mainly related to the impurity and species 
specificity of the insulin preparations [1, 13]. 
As insulin purification techniques improved, 
the duration of action of insulin decreased, and 
patients required multiple injections throughout 
the day to avoid severe glycosuria [12]. This 
often led to either poor patient adherence or 
alternating extremes of hyperglycemia and 
hypoglycemia resulting from the boluses of 
these shorter-acting formulations [12]. As 
concerns regarding hypoglycemia emerged as 
evolution of insulin development from early 
animal insulin to current investigational insulin, 
with a focus on limitations and how they were, 
or will be, overcome.
Because diabetes is a chronic condition, 
attention to patient lifestyle considerations is 
important in insulin development to better 
empower patients and improve adherence. 
Indeed, more physiologic PK/PD parameters can 
facilitate adherence by allowing dosing times 
that better fit the daily schedules of patients. 
Subcutaneous insulin administration presents 
a challenge for patients who fear the pain or 
inconvenience of injection [10], something 
that has been and continues to be addressed by 
ongoing improvements in insulin pen devices 
and needles.
As insulin has evolved, so has the definition 
of a unit of insulin. The definition of one unit 
of insulin is, “the amount of insulin that will 
lower the blood glucose of a healthy 2 kg (4.4 lb) 
rabbit that has fasted for 24 hours to 2.5 mmol/L 
(45 mg/dL) within 5 hours” [11].
LITERATURE SEARCH 
METHODOLOGY
Information for this narrative, nonsystematic 
review was gathered by reviewing clinical trial 
data. A PubMed literature search was conducted 
to identify relevant, peer-reviewed clinical and 
review articles published between 1980 and 
September 2011 related to the evolution of 
insulin development. Search terms included 
“animal insulin,” “synthetic insulin,” “regular 
human insulin,” “insulin lispro,” “insulin 
aspart,” “insulin glulisine,” “insulin glargine,” 
“insulin detemir,” “insulin degludec,” “biphasic 
human insulin,” “insulin premixes,” “ultra-long 
acting insulin,” “oral insulin,” and “inhaled 
insulin.” Case studies and editorials were 
excluded. Primary manuscripts and reviews 
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an obstacle to effective treatment with insulin, 
encouraging patients to adhere to treatment 
regimens became a priority and the driving force 
behind further insulin development.
The first slow-release insulins using the 
animal protein protamine were developed 
in 1936. These insulins reduced, but did not 
eliminate, the incidence of hypoglycemic 
episodes [14]. The first slow-release insulin, 
neutral protamine Hagedorn (NPH), was an 
intermediate-acting complex of protamine, 
a protein isolated from fish sperm that 
reduced the solubility of insulin and zinc [12]. 
NPH was originally made by combining 
protamine with animal insulin, but was later 
added to insulin that was produced using 
recombinant DNA technology. It is so named 
because NPH was developed in the Hagedorn 
Laboratory in Denmark by Nordisk in 1946 [15]. 
Interestingly, NPH was considered a long-acting 
basal agent before the development of basal 
insulin analogs although its duration of action is 
only 12–18 hours [16, 17]. In addition, with NPH 
there is a shift in the peak with larger doses due 
to the depot effect, which, clinically, is a limiting 
factor [18]. A high level of hypoglycemia, 
particularly nocturnal hypoglycemia, was and 
still is one of the major limitations of NPH [19]. 
While gains were made in patient convenience, 
the issue of hypoglycemia remained.
In the 1970s, the production of highly purified 
animal insulins reduced the insulin dose needed 
for diabetes control and partially prevented 
local reactions such as lipoatrophy [20]. 
In one study, lipoatrophy was found in 
49 of 511 (9.6%) patients with diabetes treated 
with conventional therapy, but not in those 
treated solely with very pure porcine insulin [20]. 
However, in later studies, sporadic cases of 
lipoatrophy were reported with both highly 
purified porcine and bovine insulin, indicating 
that this side effect had not been completely 
eliminated [21]. Therefore, while the insulin 
purification process decreased the incidence of 
adverse events, further improvements were still 
necessary.
Variable Efficacy and Risk of Hypoglycemia 
with Animal Insulin
Large-scale production of insulin following 
its initial discovery was challenging, partly 
due to the temperature and pH variability 
between batches. A collaboration between Eli 
Lilly and the Toronto group of Banting, Best, 
Collip, Campbell, Fletcher, Macleod, and E.C. 
Noble led to the production of more potent 
porcine insulin preparations in mid-1922 [13]. 
However, the lot-to-lot potency still varied by 
25%, so physicians had to be constantly on 
the lookout for signs of hypoglycemia from 
excessive insulin [13]. Eli Lilly and Company’s 
chief chemist George Walden developed the 
isoelectric precipitation method to improve the 
stability and purity of insulin significantly [13]. 
However, standardization problems persisted, 
with consistency from batch to batch still 
varying by 10% [13].
Insulin Efficacy Criteria
Measurements of insulin efficacy have evolved 
along with the development of new insulins. 
Before the introduction of hemoglobin A1c 
(HbA1c) in 1976 as a means of monitoring long-
term blood glucose levels [22], insulin efficacy 
was generally assessed using postprandial 
glucose (PPG) and fasting plasma glucose 
(FPG) levels. HbA1c, the measure of circulating 
glycated hemoglobin over the previous 
2–3-month period, has since become the 
standard for evaluating the success of 
diabetes treatment regimens [23]. The 
relative contributions of PPG and FPG to 
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HbA1c in patients with type 2 diabetes can 
vary depending on the HbA1c level. PPG and 
FPG should be considered individually when 
administering insulin therapy due to their 
potential for predicting other health risks. 
For example, PPG greater than 7.8 mmol/L 
in patients with normal FPG is associated 
with a two times greater risk of cardiovascular 
disease-related death [24]. However, the Long-
term Study of Nateglinide + Valsartan to 
Prevent or Delay Type II Diabetes Mellitus and 
Cardiovascular Complications (NAVIGATOR) 
trial showed that targeting PPG did not reduce 
the risk of extended composite cardiovascular 
outcomes (death from a cardiovascular cause, 
nonfatal myocardial infarction, nonfatal 
stroke, hospitalization for heart failure, arterial 
revascularization, or hospitalization for unstable 
angina) [25]. Another study, Hyperglycemia 
and Its Effect After Acute Myocardial 
Infarction on Cardiovascular Outcomes in 
Patients With Type 2 Diabetes (HEART2D), 
did show a reduction in cardiovascular 
mortality risk in elderly (>65.7 years) 
acute myocardial infarction survivors when 
targeting PPG versus FPG [26]. Therefore, HbA1c, 
PPG, and FPG might all have clinical relevance 
as measurements of insulin efficacy.
SYNTHETIC INSULINS
Synthetic insulins were developed to 
provide patients with diabetes a potentially 
more effective and more readily available 
alternative to animal insulins. Following the 
characterization of the amino acid structure of 
human insulin, synthetic insulin was produced 
in American, German, and Chinese laboratories 
in the 1960s [27–29], making insulin the 
first protein ever synthesized in vitro [30]. 
Synthetic insulin with the amino acid structure 
of human insulin is prepared using several 
techniques, including total chemical synthesis, 
semisynthesis, which involves substituting 
the alanine in porcine insulin with threonine, 
and recombinant DNA methods [31, 32]. 
In the first clinical trial of insulin produced 
by total chemical synthesis (CGP 12831), 
six patients with diabetes showed evidence of 
full biologic action of the synthetic insulin [29]. 
Ketoacidosis was corrected in one patient, and 
synthetic insulin normalized the hyperglycemia 
in a patient with poor response to oral 
antidiabetic drugs [29]. However, two patients 
experienced more sudden hypoglycemic 
events than with animal insulin [29]. 
Another study investigating the safety and 
efficacy of semisynthetic human insulin in 
healthy patients found no difference in the 
potency, onset, and duration of effect between 
semisynthetic and porcine insulins [31]. 
Furthermore, in a study of patients with type 
1 diabetes, semisynthetic insulin also showed 
no significant differences in blood glucose 
control and subcutaneous absorption compared 
with porcine insulin [32]. Together, these data 
suggested that synthetic insulins were a more 
viable option for most patients with diabetes 
than animal insulins. However, hypoglycemia 
remained a significant concern.
REGULAR HUMAN INSULINS
Advances in Insulin Production but Still 
Problems with Glycemic Control
The development of recombinant DNA 
technology finally allowed for the large-
scale synthesis of insulin. In 1978, scientists 
from Genentech used recombinant DNA 
technology to synthesize the A and B chains 
of insulin in Escherichia coli [33]. In vivo, 
insulin is synthesized from cleavage of a 
large polypeptide proinsulin that generates 
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a C peptide and covalently links the A and 
B chains of insulin together (Fig. 1) [34, 35]. 
However, when insulin is made in vitro with 
recombinant DNA technology, the A and 
B chains are synthesized separately using E. coli, 
and then joined together biochemically [33]. 
In 1982, Eli Lilly and Company [36] developed 
a short-acting insulin called Humulin R [37] 
and an intermediate-acting NPH insulin called 
Humulin N [38]. Human insulin synthesized by 
recombinant DNA technology was first tested 
in 17 healthy male volunteers [39], and it 
had similar glucose-lowering properties when 
compared to purified porcine insulin [39]. 
Therefore, RHI appeared to be a good alternative 
to animal insulin. Novo Nordisk also started 
producing biosynthetic human insulin (BHI) 
in 1987 [40].
Advances in insulin purity, species, and 
characteristics of the retarding agent were 
observed during the development of RHI [16]. 
However, the PK/PD properties of regular and 
intermediate-acting human insulin did not 
accurately match the insulin secretion pattern 
of a healthy patient without diabetes. In patients 
who do not have diabetes, insulin rises to a 
maximum concentration 30–45 minutes after 
ingestion of food, followed by a decline to 
basal levels after 2–3 hours [16]. The slow onset 
Fig. 1  Structure (a) and biosynthesis of insulin (b) [34]. 
Reprinted from the Journal of the Association of Physicians 
of India, Vol. 55, Joshi SR, Parikh RM, Das AK, “Insulin 
– history, biochemistry, physiology and pharmacology,” pp. 
20–21, 2007, with permission from Dr. Siddharth N. Shah 



































Fig. 2  Comparison of insulin time-action profiles [41]. 
Reprinted from Consultant, July 2009 Supplement, Brunton 
S, “Safety and effectiveness of modern insulin therapy: the 
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and long duration of action of RHI (Fig. 2 [41]) 
increases a patient’s risk of developing early 
postprandial hyperglycemia followed by 
hypoglycemia before the next meal [16]. The 
effect of the intermediate-acting NPH lasts 
only 12–18 hours (Fig. 2 [41]) [17], and there is 
considerable inter and intra-subject variation in 
bioavailability [16], because NPH is a suspension 
that must be mixed before injection [16, 17]. 
Even in clinical research centers, the variability of 
the glucose infusion rate approaches 68% using 
clamp data. Differences in the site of injection can 
lead to variability in the absorption of NPH [16]. 
Furthermore, in a double-blind crossover trial, 
treatment with porcine or bovine insulin was 
compared with BHI in 94 patients with diabetes [42]. 
FPG levels were higher during BHI treatment 
than during treatment with animal insulin 
(14.2 vs. 12.8 mmol/L and 12.1 vs. 9.6 mmol/L 
in the bovine and porcine groups, respectively). 
This was presumably due to the different 
pharmacokinetic properties of BHI. Consistent 
with this, previous evidence showed that BHI is 
absorbed, and likely excreted or inactivated, more 
quickly than purified porcine insulin in normal 
subjects. Patients’ willingness to adhere to 
therapy can be greatly undermined by the dosing 
inconvenience of RHI and NPH and the potential 
hypoglycemic episodes because of the extended 
duration of effect with larger doses of NPH [18, 43]. 
As RHI has a relatively slow onset, it needs to 
be administered 30–60 minutes before a meal, 
the time of which can be difficult to predict. 
Therefore, short-acting analogs that can be 
injected right before a meal were needed [16, 44]. 
Because of the limitations of both RHI and NPH 
and the need to mimic more closely the insulin 
secretion of a healthy patient, mixing NPH and 
RHI was common, but often resulted in cross-
contamination and more inter and intrapatient 
variability, leading to the development of insulin 
premixes.
Human Insulin Premixes: Improvement 
in Glycemic Control and Patient Lifestyle 
Concerns
Insulin premixes, which contain a mixture of 
intermediate and short-acting insulins in the 
same vial, were developed to improve glycemic 
control over RHI or NPH alone. They also allow 
the patient to administer fewer daily injections 
than classic basal-bolus therapy, which requires 
injections of rapid-acting insulin before meals 
and intermediate or long-acting insulin in 
the morning or at bedtime. Biphasic human 
insulin 30 (BHI 30) consists of 30% short-
acting human insulin and 70% NPH, and has 
a duration of action up to 24 hours in some 
patients and a maximum effect between 2 and 
8 hours [45, 46]. Through further innovation, 
these premixes are now available in pen devices, 
eliminating the need for separate vials and 
syringes. Administering treatment with pen 
devices has ultimately decreased patient dosing 
errors and intrapatient variability associated 
with calculating the dosage of each component 
and mixing [47]. However, the same limitations 
of RHI and NPH persist.
INSULIN ANALOGS
Development of Insulin Analogs
By the early 1990s, great strides had been 
made in the development of insulin. Although 
animal insulin decreased mortality rates from 
diabetes, availability issues and large variability 
between batches led to difficulty in determining 
proper doses and hypoglycemia. While the 
availability of synthetic insulin reduced some 
of these concerns, hypoglycemia remained 
a major issue and patients required multiple 
injections throughout the day. Furthermore, 
while recombinant DNA technology resolved 
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insulin production problems and allowed for 
the development of better retarding agents, the 
PK/PD profile of synthetic insulin still did not 
mimic endogenous insulin. Insulin premixes 
improved glycemic control, decreased intrapatient 
variability due to mixing, and required fewer 
injections per day, which was easier for patients 
to manage. However, patient adherence to 
insulin regimens was still problematic due 
to the need to inject 30–60 minutes before a 
meal, reluctance to use syringes, intrapatient 
variability with preparation of vials and syringes, 
and the inconvenience of multiple injections 
per day. Despite the development of pen devices, 
vials and syringes were still the most common 
method of administration. Therefore, new insulin 
preparations were needed that provided either a 
faster onset and shorter duration of action and 
could be administered right before meals or a 
longer-acting, flatter time-action profile to sustain 
patients between injections [16].
Insulin analogs were designed to provide 
either a basal or bolus option to stimulate normal 
insulin physiology and secretion more closely, 
Fig. 3  Molecular structure of human insulin and rapid-acting insulin types – (a) human insulin, (b) insulin lispro, (c) insulin 
aspart, and (d) insulin glulisine [49]. NPH neutral protamine Hagedorn. Reprinted from Diabetes, Metabolic Syndrome and 
Obesity: Targets and Therapy, Vol. 2, Yamada S, “Insulin glulisine in the management of diabetes,” p. 112, 2009, with permission 
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reduce hypoglycemia, and allow for improved 
absorption [2, 48]. Insulin consists of a 21 amino 
acid-long A chain and a 30 amino acid-long B 
chain (Fig. 3a) [49]. The substitution of amino acids 
at specific locations along either of these chains 
forms the basis of insulin analog production. 
Substitutions at the N terminus of the A chain 
and the C terminus of the B chain can change 
the avidity of insulin to its receptor, as these 
regions are the sites of receptor binding. In 
addition, the C terminal of the B chain is critical 
for the conversion of stable insulin hexamers 
Fig. 4  Molecular structure of long-acting insulin analogs - (a) insulin glargine, (b) insulin detemir, and (c) insulin degludec [50]. 
Reprinted from Diabetes Technology and Therapeutics, Vol. 13, Supplement 1, Owens DR, “Insulin preparations with prolonged 
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to dimers, which are further resolved into the 
absorbable monomer form. Among bolus insulin 
types, substitutions in this region can aid rapid 
absorption [49]. These substitutions include 
the reversal of the natural sequences of proline 
at position B28 and lysine at position B29 in 
insulin lispro (Fig. 3b), the natural sequences of 
proline at position B28 substituted by aspartic 
acid in insulin aspart (Fig. 3c), and the natural 
sequence of asparagine at position B3 substituted 
by lysine and glutamic acid instead of lysine at 
position B29 (Fig. 3d) in insulin glulisine [49]. 
The insulin molecules of basal analogs also 
have modifications at B30. In particular, insulin 
glargine (Fig. 4a) has elongation of the C terminus 
of the B chain, two arginine residues inserted at 
position B30, and replacement of asparagine with 
glycine at position A21, while insulin detemir 
(Fig. 4b) is produced by deleting the amino acid 
threonine at B30 of human insulin molecules 
and adding a myristic fatty acid residue to the 
ε-amino group of the lysine residue at B29 [50]. 
The newer long-acting insulin analog degludec 
has an insulin amino acid sequence that matches 
human insulin except ThrB30 is deleted and a 
16-carbon fatty diacid is attached to LysB29 with 
a glutamic acid spacer (Fig. 4c) [50]. Insulin 
analog premixes have also been developed to 
minimize patient error when combining insulins 
and to provide basal and bolus coverage in one 
injection; however, premixes might not provide 
optimal glycemic control for all patients due to 
the fixed ratio of their components [48].
PK/PD of Basal, Bolus, and Insulin Analog 
Premixes
Long-Acting Insulin Analogs More Closely 
Mimic Physiologic Basal Insulin Secretion
Basal analogs (Fig. 4 [50]) were designed to 
provide consistent, flat, long-acting insulin 
levels to mimic the constant release of insulin 
that regulates endogenous glucose output [48]. 
Two basal insulin analogs, insulin glargine and 
insulin detemir, are currently available [48]. In 
solution, insulin glargine has an acidic pH (pH 4) 
and upon subcutaneous injection the acidic 
solution becomes neutralized thereby forming 
microprecipitates. This contributes to the slow 
release of insulin glargine into the circulation [48]. 
With insulin detemir, acylation of the molecule 
gives it a high binding affinity for albumin, 
which delays its absorption [50]. In solution, 
insulin detemir has a neutral physiologic 
pH (pH 7.4) and its hexamer-forming abilities 
together with its reversible albumin binding 
result in prolonged insulin action [51]. Both 
insulin detemir and insulin glargine exhibit 
prolonged (up to 24 hours) duration of 
action [52, 53] and little peak activity compared 
to NPH (Fig. 2 [41]) [54, 55], but the duration 
of action for insulin detemir can be as short as 
5.7 hours and the duration of action can be as 
short as 10.8 hours for insulin glargine [52, 53]. 
Plank and colleagues found that at a dose of 
0.4 U/kg, insulin detemir achieved maximal 
action at 8–10 hours with a mean end of action 
of almost 22 hours [56]. In addition, in patients 
with type 2 diabetes, Klein et al. found that the 
duration of action was dose-dependent and similar 
for both insulin glargine and insulin detemir [57]. 
Based on these findings, it is apparent that the 
majority of type 2 patients can be dosed once 
daily with these basal analogs, highlighting the 
benefit of these analogs over NPH, which was 
once considered long acting. Basal insulin analogs 
have also resolved the noticeable peak associated 
with NPH, bringing them closer to a physiologic 
basal insulin. However, some patients may require 
twice-daily dosing for both insulin detemir and 
insulin glargine as the duration of action may 
not cover 24 hours in all patients. Also, among 
patients with type 2 diabetes, time-action 
profiles of insulin detemir and insulin glargine 
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administered at 0.4, 0.8, and 1.4 U/kg as part 
of a pharmacokinetic glucose clamp study were 
found to be similar, showing duration of action 
increased with rising doses and started declining 
between 16 and 18 hours for all doses [57]. 
At the two lower doses, the duration of action 
was estimated to be below 24 hours. The authors 
note that this pharmacokinetic study should 
not be extrapolated to clinical response [57]. 
Furthermore, some healthcare providers split 
doses. On balance, true basal coverage for all 
patients has not yet been fully achieved [4].
Rapid-Acting Insulin Analogs Add to Patient 
Convenience
In response to the shortcomings of the PK/PD 
profiles of RHI, which include a slow onset of 
action, a peak effect 3 hours after dosing, and a 
duration of action beyond 8 hours, three rapid-
acting bolus insulin analogs have been developed 
to date: insulin glulisine, insulin lispro, and 
insulin aspart [58]. All three analogs have a rapid 
onset of action (within 30–60 minutes) and a peak 
action within 2 hours, compared with the onset 
of action of 45–60 minutes and peak effect of 
3 hours after RHI dosing (Fig. 2 [41]) [6, 10, 58, 59]. 
Whereas RHI must be given more than 30 minutes 
before meals, rapid-acting insulin analogs can be 
given just before a meal or even after the meal 
has begun. In a study involving type 1 diabetes 
patients treated with basal-bolus therapy, patients 
assigned to insulin aspart as their bolus therapy 
indicated a greater degree of flexibility compared 
to patients using RHI [60]. The inconvenience 
of insulin administration plays a large part in 
nonadherence to insulin regimens [48]. Because 
they have a more convenient administration 
schedule, bolus insulin analogs may improve 
patient adherence to prescribed treatments.
Insulin lispro was the first rapid-acting 
bolus insulin analog developed. The inversion 
of the lysine of B29 and the proline of B28 
of human insulin allows insulin lispro to 
dissociate rapidly into monomers and become 
quickly absorbed into the circulation [2]. As an 
alternative approach, the structure of insulin 
aspart prevents self-association into insulin 
dimers and hexamers, which increases the rate 
of absorption of the insulin monomers into the 
blood [49, 61]. For insulin glulisine, the amino 
acid alteration at positions B3 and B29 provides 
molecular stability and lowers the isoelectric 
point of insulin glulisine (pH 5.1) compared 
to RHI (pH 5.5), enhancing insulin glulisine’s 
solubility at a physiologic pH [49, 62]. Unlike 
other bolus insulin analogs, insulin glulisine 
does not contain the hexamer-promoting zinc, 
allowing for immediate bioavailability at the 
injection site [49].
Insulin lispro, insulin aspart, and insulin 
glulisine have similar PK/PD properties and 
show low intrasubject variability. In general, all 
rapid-acting analogs achieve twice the maximal 
concentration and take about half the time to reach 
maximal concentration compared to equivalent 
doses of RHI [6, 10, 63–65]. The faster and more 
intense action of the insulin analogs more closely 
mimics endogenous insulin response, which can 
lead to better control of PPG levels compared to 
RHI [6, 66]. In contrast to RHI, there is no delay 
in peak as the dose and depot increase. One study 
found that with a dose of 10 U of insulin lispro, 
the mean peak insulin action was 99 ± 39 minutes, 
as compared with 179 ± 93 minutes for RHI 
(P < 0.05) [10]. For insulin aspart, Mudaliar et al. 
reported that the time to peak insulin action was 
94 ± 46 minutes compared to 173 ± 62 minutes 
for RHI (P < 0.001) [6]. Another study found that 
in healthy subjects, insulin aspart was absorbed 
twice as quickly and reached more than double 
the serum concentrations compared to RHI [67]. 
Also, both insulin glulisine and insulin lispro had 
more rapid-acting profiles than RHI in a study 
involving 18 subjects without diabetes [63].
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Insulin Analog Premixes
Insulin analog premixes are fixed-ratio 
combinations of bolus and intermediate-acting 
insulins that were developed to simplify the 
insulin regimen and to minimize patient self-
mixing error. However, as adjustments of either 
the bolus or basal component alone are not 
possible, self-mixing still may provide slightly 
better glucose control for some patients [48]. 
Because the long-acting analogs detemir and 
glargine cannot be mixed with other insulins, 
the insulin included in analog premixes is 
normally an intermediate-acting agent such 
as a protamine aspart or lispro protamine 
suspension, obviating the clinician’s ability to 
utilize the advances made in the development 
of the long-acting insulin analogs. Insulin 
analog premixes that are currently available 
in North America and Europe include a 70/30 
insulin aspart protamine/insulin aspart mixture 
(BIAsp 30), a 75/25 insulin lispro protamine/
insulin lispro mixture (Mix 25), and a 50/50 
insulin lispro protamine/insulin lispro mixture 
(lispro 50/50). Lispro 50/50 is used much less 
frequently than either BIAsp 30 or Mix 25 [68]. 
Although both biphasic human insulin 70/30 
(BHI 30) and analog premixes contain a mixture 
of intermediate and short-acting insulins, 
analog premixes have more physiologic 
pharmacokinetic profiles and provide better PPG 
control than RHI premixes [69]. For example, 
BIAsp 30 produces a higher peak insulin level 
in the circulation more rapidly than BHI 30. In 
a study comparing the pharmacology of BHI 30, 
BIAsp 30, and Mix 25, maximal serum insulin 
concentration (Cmax) was twofold higher with 
BIAsp 30 than with BHI 30 (P < 0.001) and time 
to Cmax was 55 minutes shorter (P < 0.001) [70]. 
Cmax was also significantly higher in patients 
given Mix 25 compared to those given BHI 30, 
although the Cmax was 12% higher for BIAsp 30 
than for Mix 25 (not statistically significant) [70]. 
In healthy male subjects who received a single 
injection of 0.3 U/kg, BIAsp 30 had a significantly 
greater metabolic effect than BHI 30 [71]. To add 
to this, Heise et al. showed that BIAsp 30 had 
earlier and greater activity compared to BHI 
30 in patients with type 2 diabetes [72]. Taken 
together, these attributes of BIAsp 30 translate 
into low PPG values postinjection. Finally, 
dosing is more convenient with insulin analog 
premixes than with RHI premixes. While an 
injection-meal interval of at least 30 minutes is 
recommended when using conventional human 
premixed insulin, patient adherence to this 
recommendation is low. Newer insulin analog 
premixes (e.g., BIAsp 30), which are absorbed 
rapidly from the subcutis, can be injected 
immediately before eating or even after the start 
of a meal [69].
Safety
Rapid-Acting (Bolus) Insulin Analogs Reduce 
Nocturnal Hypoglycemia, but not Severe 
Hypoglycemia
Hypoglycemia is a major concern for patients 
with diabetes and is divided into three different 
categories: minor (nonsevere) hypoglycemia, 
severe hypoglycemia,  and nocturnal 
hypoglycemia. However, according to the 
American Association of Clinical Endocrinologists 
(AACE), hypoglycemia can be difficult to assess as 
there is no consensus as to what constitutes low 
plasma glucose levels [73]. While symptoms of 
severe hypoglycemia are generally recognizable, 
mild-to-moderate hypoglycemia may remain 
asymptomatic and unreported. The American 
Diabetes Association (ADA) Workgroup on 
Hypoglycemia further characterizes hypoglycemia 
as severe hypoglycemia, documented symptomatic 
hypoglycemia, asymptomatic hypoglycemia, 
probable symptomatic hypoglycemia, and relative 
hypoglycemia (Table 1) [74]. It is also important to 
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note that defects in the glucose counterregulatory 
response, including a lack of both decreased 
insulin and increased glucagon and an attenuated 
epinephrine response, in patients with type 1 
diabetes, can cause hypoglycemia unawareness. 
Among patients with type 1 diabetes, glucagon 
response to hypoglycemia is usually blunted 
within 1–5 years of onset of the disease, and is 
usually absent within 15–30 years [75, 76]. Among 
patients intensively treated with insulin and those 
newly diagnosed with type 1, the loss of glucagon 
responses during periods of hypoglycemia may be 
due to “hypoglycemia-associated autonomic failure” 
[75, 77]. As type 2 diabetes progresses and the 
duration of insulin use lengthens, hypoglycemia, 
including the asymptomatic variety, becomes more 
frequent [78–80]. This loss of warning symptoms 
obviates any opportunity for the patient to take 
corrective action [74]. Therefore, even minor 
hypoglycemic events may impair the ability of a 
patient to recognize the hypoglycemic symptoms. 
Severe hypoglycemia has the generally accepted 
definition of requiring the assistance of another 
person [74]. Nocturnal hypoglycemia may occur 
during the time period after a bedtime injection 
and before eating breakfast or the administration 
of any oral antihyperglycemic agent in the 
morning; this type of hypoglycemia is the one 
most feared by patients. Hypoglycemia was very 
prevalent before the development of insulin 
analogs and continues to be ever present and 
a clinical challenge even with the advances in 
hypoglycemic management afforded by analogs. 
According to one meta-analysis, a significant 
reduction in the risk of nocturnal hypoglycemia 
was associated with insulin aspart treatment 
compared with RHI treatment (relative risk [RR] 
0.67; 95% CI 0.54–0.83), although no difference 
in severe hypoglycemia was reported [81]. Brunetti 
et al. also found a similar and low rate of severe 
nocturnal hypoglycemia in patients treated with 
either insulin lispro or RHI in addition to basal 
Table 1  ADA Workgroup on Hypoglycemia: classification of hypoglycemia in people with diabetes [74]
Classification Description
Severe hypoglycemia An event requiring assistance of another person actively to administer 
carbohydrate, glucagon, or other resuscitative actions. Plasma glucose 
measurements may not be available during such an event, but neurological 
recovery attributable to the restoration of plasma glucose to normal is 
considered sufficient evidence that the event was induced by a low plasma 
glucose concentration.
Documented symptomatic hypoglycemia An event during which typical symptoms of hypoglycemia are accompanied 
by a measured plasma glucose concentration ≤3.9 mmol/L.
Asymptomatic hypoglycemia An event not accompanied by typical symptoms of hypoglycemia but with 
a measured plasma glucose concentration ≤3.9 mmol/L.
Probable symptomatic hypoglycemia An event during which symptoms typical of hypoglycemia are not 
accompanied by a plasma glucose determination but that was presumably 
caused by a plasma glucose concentration ≤3.9 mmol/L.
Relative hypoglycemia An event during which the person with diabetes reports any of the 
typical symptoms of hypoglycemia and interprets those as indicative of 
hypoglycemia, with a measured plasma glucose concentration  
>3.9 mmol/L but approaching that level.
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insulin glargine [82]. Rapid-acting insulin analogs 
can thus decrease rates of nocturnal hypoglycemia 
but no difference has been found in rates of severe 
hypoglycemia between rapid-acting insulin 
and RHI.
Basal Insulin Analogs Reduce the Incidence of 
Hypoglycemia
Several studies indicate that the risk of nocturnal 
hypoglycemia is reduced by using basal insulin 
analogs as compared to NPH. In a study by 
Riddle and colleagues, patients with type 2 
diabetes who were already on oral therapy were 
randomly assigned to either insulin glargine 
or NPH [83]. Rates of nocturnal hypoglycemia 
and other symptomatic hypoglycemia were 
lower with insulin glargine. In addition to 
the demonstrated reduction in the rates of 
hypoglycemia, cardiovascular safety has been a 
question with regard to exogenous insulin use. 
The results of the long-term Insulin Glargine 
(rDNA Origin) Injection versus Pioglitazone as 
add-on Therapy in Patients Failing Monotherapy 
With Sulfonylurea or Metformin (ORIGIN) study 
demonstrated that after a median follow-up 
period of 6.2 years, when used to treat FPG, 
insulin glargine was found to have a neutral effect 
on cardiovascular outcomes [84]. In an analysis 
of multiple studies comparing insulin detemir 
with NPH in type 1 diabetes, the risk reduction 
for nocturnal hypoglycemia was reported to be 
approximately 30%. Rate reductions are even 
greater for patients with type 2 diabetes [85–87]. 
Reductions in hypoglycemia may be related 
in part to insulin detemir’s reduced glycemic 
variability, or to the lack of an insulin peak when 
compared with NPH. Pieber et al. compared 
once-daily insulin glargine and twice-daily 
insulin detemir in patients with type 1 diabetes 
and found that the overall risk of hypoglycemia 
was similar after the administration of either 
insulin [3]. However, the risks of both severe and 
nocturnal hypoglycemia were significantly lower 
with insulin detemir than with insulin glargine 
(72% and 32% reduction, respectively, P < 0.05). 
Therefore, insulin detemir may be more effective 
in reducing nocturnal hypoglycemia than 
insulin glargine in patients with type 1 diabetes, 
but further studies are needed to clarify this.
Insulin Analog Premixes Reduce Hypoglycemia 
in Certain Patient Populations
A systematic review comparing insulin analog 
premixes (BIAsp 30, Mix 25, lispro 50/50) 
with RHI premixes found that the overall 
hypoglycemia risk was similar for many 
populations of patients with type 2 diabetes 
[88]. However, several noninferiority studies 
found hypoglycemic benefits of analog premixes 
compared to RHI premixes in patients under 
more challenging glucometabolic conditions 
[88]. Clinical studies have yielded variable 
results regarding the risk of hypoglycemia 
following the administration of BIAsp 30. In 
one meta-analysis, rates of overall hypoglycemia 
were not significantly different between BIAsp 
30 and BHI 30 in patients with type 2 diabetes 
[89]. However, in the same study, the rate of 
nocturnal hypoglycemia was 50% lower for 
BIAsp 30 than for BHI 30 (rate ratio 0.50; 95% 
CI 0.38–0.67; P < 0.01). In addition, for BIAsp 
30, the likelihood of major hypoglycemia was 
significantly lower compared to BHI 30 (odds 
ratio 0.45; 95% CI 0.22–0.93; P < 0.05). In this 
study, the rate of daytime hypoglycemia was 
24% lower with BHI 30 than BIAsp 30 (rate 
ratio 1.24; 95% CI 1.08–1.43; P < 0.01) [89]. In 
another study, the incidence ratio for reported 
hypoglycemia for BIAsp 30 was significantly 
lower compared with BHI 30 in insulin-naive 
type 2 diabetes patients (0.74; 95% CI 0.62–
0.89; P = 0.001), but in other patients, the 
difference in reported hypoglycemia was not 
significant between BIAsp 30 and BHI 30 [90]. 
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In the Observational Study of Safety and 
Effectiveness of NovoMix® 30 (Biphasic Insulin 
Aspart) for the Treatment of Diabetes Mellitus 
(IMPROVE) observational study of patients 
with type 2 diabetes, major hypoglycemia was 
reduced in insulin-naive patients who started 
on BIAsp 30 and in those who switched to 
BIAsp 30 from another insulin [91]. These data 
suggest that insulin analog premixes can reduce 
the risk of nocturnal and major hypoglycemia 
in patients with type 2 diabetes and overall 
hypoglycemia in certain patient populations.
Efficacy/Variability
Bolus Insulin Analogs Improve Glycemic 
Control
Several studies have found that rapid-acting insulin 
analogs provide better glycemic control than RHI 
or NPH. A meta-analysis of 13 studies found that 
in patients with type 1 diabetes, HbA1c levels were 
lower with insulin aspart than with RHI [81]. 
For patients with type 2 diabetes, PPG was 
significantly lower in the insulin aspart group than 
in the RHI group in nine studies [81]. In addition, 
insulin lispro and insulin aspart are more effective 
than RHI in lowering HbA1c levels in patients 
who receive continuous subcutaneous infusion 
of insulin [92, 93]. An analysis of noninferiority, 
randomized, controlled trials obtained via a search 
of PubMed and congress proceedings showed that 
rapid-acting insulin analogs (insulin glulisine, 
insulin aspart, and insulin lispro) were either 
noninferior to or provided greater improvements 
in glycemic control than RHI in a basal-bolus 
regimen [94]. All of the trials in this analysis were 
designed to be noninferiority trials according to 
US Food and Drug Administration (FDA) guidance 
for diabetes studies. Rapid-acting insulin analogs 
are clinically superior and are recommended by 
AACE and the ADA instead of RHI because they 
cause less hypoglycemia [73, 95].
Basal Insulin Analogs Improve Glycemic 
Control
Both insulin glargine and insulin detemir have 
shown similar improvement in HbA1c and 
FPG levels compared with NPH [68]. However, 
treatment with insulin glargine resulted in less 
intersubject variability in the rates of glucose 
infusion needed to maintain proper glycemic 
levels compared to the intersubject variability in 
rates of glucose infusion for NPH [96]. In addition, 
in a randomized, open-label trial involving 
595 patients with type 1 diabetes, glycemic 
control was improved with an insulin detemir/
insulin aspart combination compared with 
NPH/RHI (HbA1c 7.8% vs. 8.11%, P < 0.001) [97]. 
Intrapatient daily variation in plasma glucose was 
also lower with insulin detemir/insulin aspart than 
with NPH/RHI [97]. Taken together, these results 
suggest that insulin glargine and insulin detemir 
are more effective for glycemic control than NPH.
Insulin Analog Premixes
Studies have shown that insulin analog premixes 
BIAsp 30 and Mix 25 provide HbA1c control 
to a similar extent as BHI 30 [71]. In a study 
involving patients with type 2 diabetes, BIAsp 
30 provided better PPG control compared with 
either BHI 30 or Mix 25 [92]. Mix 25 also limited 
PPG excursions more effectively than did BHI 30 
in a pharmacodynamic study [68]. BIAsp 30 was 
associated with improved HbA1c levels compared 
with BHI 30 in insulin-naive patients with type 2 
diabetes, type 1 diabetes patients, or insulin-
experienced patients with type 2 diabetes [90]. 
In addition, while the analog premixes can be 
given three times a day, RHI premixes cannot. 
A study by Heise et al. showed that glucose 
infusion rates for BIAsp 30 approximated basal 
bolus with three injections [72]. Analog premixes 
may thus be a more effective choice than human 
premixes for some patients.
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HIGH CONCENTRATION INSULIN
U-500 Regular Insulin
Severe insulin resistance is a condition in which 
a patient with diabetes requires more than 
200 units of insulin daily. Obesity is one of the 
most common causes of insulin resistance [98]. 
Severe insulin resistance is difficult to treat 
successfully, and to achieve good glycemic control 
in this patient population, large doses of insulin 
are required daily, which can result in leakage 
and poor absorption. Moreover, large-volume 
injection may cause discomfort and, consequently, 
poor compliance [99]. The need for high insulin 
concentration was evident and this need prompted 
the development of U-500 regular insulin.
Bovine U-500 regular insulin (Iletin; Eli 
Lilly and Company, Indianapolis, Indiana, 
USA) was first introduced in the USA in 
1952. The current recombinant human 
regular U-500 (U-500R) insulin preparation 
(Humulin R U-500; Eli Lilly and Company), 
which is available in 500 units/mL, 
became available in the USA in 1997. U-500 
regular insulin is fivefold more concentrated 
than U-100 regular insulin and, thus, the 
administration of 100 units of U-500 requires 
an injection volume of 0.2 mL compared with 
1 mL for U-100 regular insulin. The smaller 
injection volume plays a role reducing the 
potential of leakage and increasing the potential 
for absorption [100]. Use of U-500R increased 
significantly in recent years, reflecting the 
increasing number of patients requiring high 
insulin doses. A randomized, double-blind, 
crossover euglycemic clamp study compared 
the pharmacokinetics and pharmacodynamics 
of single subcutaneous injections of 50 and 
100 unit doses of U-500R and U-100R in 
healthy obese subjects [101]. Both formulations 
produced relatively long durations of 
action (18.3–21.5 hours). Time to peak 
concentration and time to maximum effect were 
significantly longer for U-500R than U-100R 
at the 100 unit dose (P = 0.05). Time variables 
reflective of duration of action (late tRmax50, tRlast) 
favored U-500R at both doses (P = 0.05). The 
authors of this study and the authors of a similar 
study concluded that subcutaneous injection of 
U-500R insulin was similar to U-100R insulin; 
however, U-500R, peaks of concentration and 
action profiles were blunted and the effect after 
the peak was prolonged [98, 101].
Statistical analysis of eight clinical studies 
conducted on U-500 regular insulin was 
performed by Lane et al. and showed significant 
reductions in HbA1c (P ≤ 0.001) and increases in 
weight (P = 0.002) [100]. These results are similar 
to that typically observed with U-100 insulin 
therapy. Nonsignificant increases in total insulin 
dose were observed in the 3–98 months after 
patients were switched to U-500 regular insulin 
administered either by subcutaneous injection 
or by continuous subcutaneous insulin infusion 
[100]. Lowery et al. investigated the changes in 
HbA1c, weight, and total daily insulin dose (TDD) 
following the initiation of insulin U-500 alone 
or as part of a basal/bolus insulin regimen [102]. 
The study showed reductions in HbA1c (9.5% at 
baseline vs. 7.7% at 6–9 months, P < 0.0001) and 
increases in weight (128.8–32.7 vs. 131.5–31.3 kg, 
P < 0.014) and TDD (260–111 to 333–106 units/
day, P < 0.0002). The authors concluded that 
U-500 resulted in improvements in HbA1c and 
weight gain and increased TDD when used alone 
or as part of combination insulin therapy [102].
INVESTIGATIONAL INSULINS AND 
THE FUTURE OF INSULIN THERAPY
The development of insulin analogs improved 
glycemic control and reduced nocturnal 
hypoglycemia, but further improvements are 
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still necessary. While current basal insulin analogs 
have advantages over NPH, these analogs still do 
not have a completely flat profile, and do not 
achieve 24-hour insulin coverage in all patients 
[103]. Although hypoglycemia is reduced with 
insulin analog treatment, it remains an important 
limitation that can lead to increased food intake 
and decreased insulin dosage, with patients 
ultimately not meeting their fasting targets [104]. 
Unrecognized hypoglycemia, including nocturnal 
hypoglycemia, can be particularly dangerous. 
A major goal of investigational insulin therapies 
is to provide optimal basal insulin coverage that 
mimics the physiologic insulin secretion profile. 
Flexibility and convenience in dosing regimens 
and insulin administration techniques are also 
important factors to consider in the development 
of next-generation insulins.
Ultra-Long-Acting Basal Insulin
Insulin degludec, the only ultra-long-acting basal 
insulin, is currently in phase 3 development 
(Fig. 4 [50]) [105]. The method of protraction 
involves the slow release of insulin degludec 
monomers from the multihexamers that only 
form after subcutaneous injection, resulting in an 
ultra-long duration of action over 42 hours, a long 
half-life (>24 hours), and a smooth and stable 
pharmacokinetic profile at steady state [104, 106]. 
These multihexamers also provide a buffer against 
changes in absorption rate, which contributes 
to the stable and consistent pharmacokinetic 
profile [104]. The half-life of a drug is particularly 
important when evaluating the potential for 
accumulation. Because plasma concentration 
decreases by 50% for each half-life [107], 
matching dosing frequency with the half-life of 
a long-acting basal insulin can reduce the risk 
of inappropriate stacking. Once a steady state is 
reached, the amount of insulin eliminated over 
a 24-hour period will equal the amount injected.
The formation of multihexamers is the 
primary differentiator in the protraction of effect 
between the current basal insulin analogs and 
insulin degludec. A phase 1 trial comparing the 
pharmacokinetic profile of insulin degludec to 
insulin glargine found that degludec had a twofold 
longer half-life and a more stable pharmacokinetic 
profile with minimal fluctuations [108]. One-
year results from two phase 3 treat-to-target trials 
investigating the noninferiority and safety of 
insulin degludec [109, 110] have shown similar 
efficacy between insulin degludec once daily 
and insulin glargine once daily in patients with 
type 1 or type 2 diabetes. In type 1 diabetes 
patients, overall glycemic control was improved 
as evidenced by a 0.4% reduction in HbA1c for 
patients on insulin degludec or insulin glargine and 
a similar proportion of subjects achieving HbA1c
less than 7% [109]. In type 2 diabetes patients 
on basal-bolus therapy with insulin aspart as the 
bolus insulin, insulin degludec improved overall 
glycemic control at comparable rates to insulin 
glargine, and in both treatment groups HbA1c less 
than 7% was reached in 49% of subjects [110]. 
In addition, insulin degludec and insulin glargine 
reduced FPG by 1.3 mmol/L and 1.44 mmol/L, 
respectively, in type 1 diabetes patients [109], 
and by 2.3 mmol/L and 2.0 mmol/L, respectively, 
in type 2 diabetes patients [110]. As these were 
treat-to-target trials with FPG as the titration 
target, differences in HbA1c and FPG were not 
expected between insulin degludec and insulin 
glargine in either trial. Rates of nocturnal 
confirmed hypoglycemia (plasma glucose <3.1 
mmol/L or severe episodes as per ADA definition) 
were 25% lower with insulin degludec (4.4 vs. 
5.9 episodes/patient year [109] and 1.4 vs.
1.8 episodes/patient year [110]) compared with 
insulin glargine in both studies. Another trial 
evaluated the noninferiority of insulin degludec 
dosed once daily in a flexible regimen (degludec 
flex) compared to insulin glargine given according 
Adv Ther (2012)  29(7):590–619. 607
to the FDA-approved prescribing information – 
once daily at the same time each day, with time 
of day decided by the physician and patient [111]. 
The flexible regimen involved a forced rotation 
of insulin degludec dosing between morning and 
evening, resulting in 8–40 hour dosing intervals. 
At 26 weeks, insulin degludec flex and insulin 
glargine once daily reduced HbA1c by 1.28% and 
1.26%, respectively, confirming the noninferiority 
of insulin degludec flex compared to insulin 
glargine. For insulin degludec flex, the mean FPG 
at 26 weeks was significantly lower compared to 
insulin glargine once daily. Even with this extreme 
range in dosing times (8–40 hours between doses) 
rates of confirmed hypoglycemia (3.6 episodes 
with degludec vs. 3.5 episodes with glargine) 
and nocturnal hypoglycemia (0.6 episodes with 
degludec vs. 0.8 episodes with glargine) were 
similar between the insulin degludec flex and 
insulin glargine groups, indicating that insulin 
degludec can be injected whenever convenient 
for the patient without compromising glycemic 
control [111]. A phase 1 trial comparing the 
pharmacokinetic profile of insulin degludec to 
insulin glargine found that insulin degludec had a 
half-life of 25.4 hours compared to only 12.5 hours 
for insulin glargine [108]. That study showed a 
consistent and flat profile as evidenced by the 
equal distribution of serum exposure to insulin 
degludec between the first and second 12 hours 
post-dosing and no stacking [108]. While the long 
duration of action of insulin degludec may raise 
concerns for hypoglycemia, several phase 3 clinical 
studies of insulin degludec have demonstrated 
a low risk of hypoglycemia, specifically 
nocturnal hypoglycemia, compared with insulin 
glargine [109–111]. In addition, results are promising 
from phase 2 trials combining two analogs, insulin 
degludec with insulin aspart [103, 112, 113]. 
One 16-week, treat-to-target, open-label trial 
evaluated the safety and efficacy of insulin 
degludec (70%)/insulin aspart (30%) (IDegAsp) 
compared to BIAsp 30 both dosed twice daily 
in patients with type 2 diabetes [112]. The rate 
of confirmed hypoglycemia was 58% lower for 
IDegAsp than for BIAsp 30, while the mean FPG was 
0.98 mmol/L lower for IDegAsp than for BIAsp 30. 
In another phase 2 trial comparing IDegAsp 
to insulin glargine in a 16-week, open-label 
trial in patients with type 2 diabetes, a similar 
number of patients achieved an HbA1c less than 
7.0% in the last 4 weeks of treatment without 
any confirmed hypoglycemia [103]. Although 
mean FPG was similar for IDegAsp and insulin 
glargine, mean plasma glucose levels 2-hours 
post-dinner were lower for IDegAsp (0.13 mmol/L) 
than for insulin glargine (1.63 mmol/L). 
A phase 3, treat-to-target, 26-week, open-label 
trial compared IDegAsp dosed once daily at 
any meal with insulin aspart at the remaining 
meals to insulin detemir with insulin aspart at 
all meals in patients with type 1 diabetes [113]. 
HbA1c improved and FPG decreased to similar 
levels in both groups. Rates of confirmed 
hypoglycemia were similar for both IDegAsp and 
insulin detemir, but rates of nocturnal confirmed 
hypoglycemia were 37% lower for IDegAsp than 
insulin detemir. It is noteworthy that this is the 
first and only insulin analog premix in which each 
insulin retains its individual characteristics.
U-200 Insulin
Insulin degludec is being developed in both 
100 U/mL and 200 U/mL (U-100 and U-200) 
formulations for once-daily use in all patients 
with diabetes. U-100 covers the insulin 
requirements for many patients, whereas U-200 
specifically benefits patients who require more 
than 80 U of basal insulin per injection, which 
is the dose limitation with currently available 
insulin delivery devices; 160 U of U-200 can be 
administered in a single injection using a newly 
developed prefilled pen. The PK/PD properties 
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of U-200 dosed at 0.6 U/kg in subjects with 
type 2 diabetes (n = 16, mean: body mass index, 
30 kg/m²; HbA1c, 7.3%) who received U-200 
once daily over 6 days were studied [114]. The 
glucose-lowering effect of U-200 was shown to 
be evenly distributed over the dosing interval. 
The effect of insulin degludec extended beyond 
26 hours in all subjects, as blood glucose stayed 
close to the target level throughout the clamp, 
and the terminal half-life at steady state was 
26.2 hours. Finally, U-200 was well tolerated 
and safe, with no injection site reactions. The 
authors concluded that U-200 has a flat and 
stable glucose-lowering effect with a duration of 
action beyond 26 hours in people with type 2 
diabetes. The bioequivalence (post-hoc analysis) 
between both U-100 and U-200 was studied in a 
randomized, double-blind, two-period crossover, 
and multiple-dose study in 33 subjects with 
type 1 diabetes. The study demonstrated that 
the two concentrations of insulin degludec 
were bioequivalent and had a similar total 
glucose-lowering effect. Because the glucose-
lowering effect and pharmacokinetic exposure 
were evenly distributed across a 24-hour dosing 
interval for both concentrations, the study 
investigators suggested that U-100 and U-200 
can be used interchangeably in clinical practice. 
The study also suggested that the availability 
of U-200 could increase the number of patients 
with type 2 diabetes who can rely on a single 
basal insulin injection daily to meet their 
24-hour insulin requirements [115].
Long-Acting Insulin Lispro
The long-acting insulin LY2605541 (LY) in 
development is a PEGylated version of insulin 
lispro, which has been designed to have a large 
hydrodynamic size to delay insulin absorption 
and to reduce its clearance and, consequently, 
result in prolonged duration of action. 
Hypoglycemia and glucose variability were 
assessed in a subset of patients from a phase 2, 
randomized, open-label, parallel study of 
LY (n = 51) or insulin glargine (n = 25) [116]. 
At 12 weeks, LY-treated patients spent less time 
with interstitial glucose below 70 mg/dL than 
glargine-treated patients during the nocturnal 
period (11 ± 5 vs. 38 ± 13 minutes, P = 0.024) 
and during the 24-hour period (25 ± 6 vs. 83 ± 
16 minutes, P < 0.001). Significantly fewer LY 
than glargine-treated patients experienced any 
hypoglycemia (50.0% vs. 78.3%, P = 0.036), 
including nocturnal hypoglycemia (20.5% vs. 
47.8%, P = 0.027); however, both treatments 
resulted in similar mean glucose values. 
LY-treated patients had significantly lower intra-
day glucose standard deviation at 12 weeks 
compared to glargine-treated patients for both 
nocturnal (1.00 ± 0.07 vs. 1.35 ± 0.16 mmol/L, 
P = 0.061) and diurnal (2.03 ± 0.10 vs. 2.50 ± 
0.18 mmol/L, P = 0.039) periods. The authors 
concluded that treatment with LY resulted in 
fewer patients with hypoglycemia and less time 
spent in hypoglycemia, as well as lower intra-
day glucose variability compared with treatment 
with glargine [116]. In addition, LY treatment 
resulted in weight loss [117].
Inhaled Insulin
Inhaled insulin delivery systems can provide 
a noninvasive alternative for patients with 
diabetes, and can be especially helpful for 
patients who are fearful of injections. Inhaled 
insulin can also circumvent the inconvenient 
regimen of multiple daily injections required by 
subcutaneous insulin therapies. Several inhaled 
insulin delivery systems have been developed, 
but much of the investigation in this area has 
been halted or postponed. Pfizer’s Exubera was 
the first inhaled insulin to receive FDA approval 
in 2006. Although Exubera showed clinical 
Adv Ther (2012)  29(7):590–619. 609
efficacy in glycemic control and low risk of 
hypoglycemia [118, 119], it was pulled from 
the market due to poor uptake and acceptance 
by both patients and prescribers [120]. 
The AERx insulin diabetes management 
system of Novo Nordisk Inc. generates insulin 
droplets for pulmonary delivery. A randomized 
trial found that AERx inhaled insulin was 
noninferior to subcutaneous insulin in 
lowering HbA1c levels, but the AERx system 
was associated with a higher risk of nocturnal 
hypoglycemia [121]. Further investigations 
of AERx have been discontinued [120]. 
Technosphere insulin (TI), another inhaled 
insulin, was compared in a randomized, 
open-label study to the efficacy and safety of 
subcutaneous RHI in covering prandial insulin 
needs. TI significantly improved PPG levels and 
had a more favorable PK/PD profile compared 
with subcutaneous RHI [122]. The TI system 
is currently undergoing phase 3 trials, and a 
placebo formulation has been developed for 
double-blind, placebo-controlled studies [120].
Oral Insulin
Oral insulin can provide a convenient method of 
administration, potentially leading to improved 
glycemic control for patients with poor 
adherence to subcutaneous insulin regimens. 
Physiological barriers of the gastrointestinal 
tract pose a major challenge for the optimal 
delivery of oral insulin [8]. Gut enzymes such 
as pepsin and trypsin break down insulin into 
its constituent amino acids, thereby abolishing 
insulin activity [8]. The tightly packed 
columnar cells and thick layer of mucin of the 
gastrointestinal tract create another barrier by 
preventing insulin absorption [8]. A major goal 
in the development of oral insulins is to bypass 
these natural defense mechanisms to allow for 
insulin entry into the gastrointestinal tract.
Several oral insulins are currently under 
investigation. IN-105, an oral insulin analog 
delivered in tablet form, was found to 
demonstrate a dose-dependent decrease in PPG in 
patients with type 2 diabetes [123]. Another oral 
insulin formulation with 4-CNAB had a faster 
onset and shorter duration of action compared 
with subcutaneous RHI, but intersubject 
variability in absorption was relatively high [124]. 
In general, oral insulin is showing promising 
results in clinical trials and could improve patient 
satisfaction with insulin treatments.
MITOGENIC ACTIVITIES OF 
INSULIN
Diabetes and Cancer Risk
An increasing number of epidemiological studies 
have explored the relationship between diabetes 
and cancer. Patients with type 2 diabetes have 
an increased risk of mortality from various solid 
tumors, including colon, liver, pancreas, bladder, 
and female breast [125–131]. The association 
between diabetes and cancer is complicated by 
confounding variables, particularly metabolic 
syndrome, including obesity and insulin 
resistance [132, 133]. These comorbidities 
can independently increase the risk of certain 
cancers, such as hepatocellular, esophageal, 
and colon [134]. In addition, insulin therapy 
may influence the cancer risk associated with 
diabetes. For example, chronic insulin therapy 
increases the risk of colorectal cancer in patients 
with type 2 diabetes [135].
Metabolic and Mitogenic Potential of Insulin 
Therapy
Insulin therapy is an important and, often, a life-
saving therapy for patients with diabetes. The 
molecular mechanisms by which insulin and 
hyperinsulinemia, whether in cell culture or in vivo 
610 Adv Ther (2012)  29(7):590–619.
lead to mitogenicity are caused by the ability of 
insulin to bind to insulin receptor and, to a much 
lesser degree, to bind to insulin-like growth factor 
1 (IGF-1) receptor [136]. Because the insulin 
receptor and IGF-1 receptor share 80% sequence of 
homology at the beta subunit and both receptors 
are members of the receptor tyrosine kinase family, 
insulin has the theoretical potential to induce a 
cell proliferation response. Potentiating the action 
of IGF-1 (epidermal growth factor, platelet derived 
growth factor, and vascular endothelial growth 
factor) by insulin has been observed in a variety 
of tissues, including vascular smooth muscle cells 
and breast cancer cells, among others [137–141]. 
Therefore, enhanced cellular responsiveness to 
growth factors is a physiological effect of insulin. 
This response becomes pathological in response to 
endogenous or exogenous hyperinsulinemia [142]. 
However, it is important to note that the clinical 
relevance and implications of insulin binding 
to the IGF-1 receptor are still not completely 
elucidated.
Insulin Analogs and Cancer
Insulin analogs are created by recombinant 
DNA technology in order to generate insulins 
with pharmacokinetic profiles that simulate 
the different phases of endogenous secretion 
of insulin. Several insulin analogs have been 
developed in recent years. Modification of the 
insulin molecule not only alters its metabolic 
effect, but it can also change its mitogenic 
potency [143]. A study of patients without known 
malignant disease who had received first-time 
therapy for diabetes exclusively with human 
insulin, aspart, lispro or glargine was conducted 
to study the effect of these insulin products on 
neoplasms [143]. The study showed a positive 
association between cancer and insulin dose for 
all insulin types. Glargine had a dose-dependent 
increase in cancer risk compared with human 
insulin (P < 0.0001), whereas lispro and aspart 
did not show an increased risk of cancer [143]. 
The relationships between insulin and cancer 
are not definitive and are often conflicting 
when a specific cancer and use of insulin were 
examined. Some studies have shown a positive 
correlation between insulin use and colorectal 
carcinoma [135, 144–146], pancreatic cancer [147], 
and liver cancer [148]. Other studies have shown 
no association between insulin therapy and 
pancreatic cancer [149] or prostate cancer [150]. 
The ORIGIN study, however, the first long-term 
study to assess this question, demonstrated 
a neutral effect on cancers after more than 
6 years of insulin glargine use [84]. An inverse 
association was seen in one study assessing the 
risk of pancreatic cancer and insulin use [151]. The 
variations seen in these studies can be explained 
by the complexity of this issue and differing study 
populations, comorbid conditions, environmental 
influences, and study durations. Although 
these and other studies have demonstrated the 
association between both endogenous insulin 
and exogenous insulin therapy and the risk of 
cancer or tumor progression, randomized, long-
term studies are needed to evaluate further the 
safety of insulin analogs and establish with 
certainty the effect of diabetes therapies on cancer 
progression. Therefore, molecular characteristics 
of insulin analogs during safety evaluation play 
an important role in identifying the mitogenic 
activities of these analogs [152]. The molecular 
characteristics of the basal insulin analogs glargine 
and detemir compared with human insulin, IGF-1, 
and the super-mitogenic insulin X10 were 
assessed by measuring the binding of ligands 
to membrane-bound and solubilized receptors, 
receptor activation, and mitogenicity in a number 
of cell types [152]. The study demonstrated that 
the molecular characteristics of glargine and 
detemir do not differ from human insulin, and 
neither analog has an increased mitogenic effect in 
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cells that predominantly express insulin receptor. 
X10 and glargine displayed an increased relative 
binding affinity for the IGF-1 and, consequently, 
exhibit increased mitogenic activities. X10 is more 
mitogenic than human insulin in both insulin 
receptor and IGF-1 receptor-expressing cells. The 
authors concluded that none of the molecular data 
presented in this study suggest any safety concern 
with detemir [152].
CONCLUSION
Animal insulin products were the first type 
of insulin available for treating patients with 
diabetes; however, their impurities were 
associated with side effects. In order to address 
those concerns, the development of synthetic 
and recombinant “human” insulins provided 
greater purity and substantially decreased 
the risks of insulin allergy and lipoatrophy. 
Eventually, long-acting insulin analogs were 
developed to provide a longer duration of 
action, along with less intrapatient variability, 
pronounced peak in time-action profiles, and 
risk of hypoglycemia than their human-derived 
counterparts. There are several current trials 
demonstrating that an ultra-long-acting insulin 
analog in development is safer, based on reduced 
incidence of hypoglycemia, and as effective as 
currently available basal insulin analogs. Because 
many patients with diabetes still have difficulty 
reaching and maintaining glycemic control on 
currently available insulins, new insulin options 
are a welcome addition, particularly those such 
as insulin degludec, which may also provide 
patients greater flexibility in time of dosing.
Long-acting and rapid-acting insulin 
analogs better simulate endogenous insulin 
secretion, and can provide both basal and bolus 
coverage when used as a premixed formulation. 
Insulin premixes offer improved glycemic 
control, decreased intrapatient variability 
versus self-mixing, and the potential for fewer 
injections per day. In addition, rapid-acting 
insulin analogs can be taken right before a meal 
and long-acting insulin analogs more closely 
mimic the normal physiologic insulin response 
due to their flatter time-action profiles.
While there have been many advances in 
efficacy, safety, and now even patient flexibility 
and convenience based on pharmacokinetics and 
mechanisms of delivery since the first insulins 
became available, more improvements are needed 
and are likely to emerge. Inhaled or oral insulin 
currently in development can further add to 
patient convenience. Additional studies are needed 
to obtain more clinically relevant information 
on optimal treatment strategies for patients with 
diabetes who are treated with insulin. The potential 
advantages associated with new types of basal 
insulin analogs and routes of insulin delivery that 
have shown promising efficacy results with low 
rates of hypoglycemia and other adverse events in 
clinical trials indicate the need for further research. 
Because diabetes mellitus is associated with an 
increased risk of macrovascular complications, 
reducing long-term cardiovascular complications 
in this patient population becomes an important 
goal of disease management. Premarketing studies 
demonstrating macrovascular risk reduction 
without cardiovascular adverse effect may delay 
availability of many effective antidiabetic drugs. 
Therefore, to expedite the approval and release of 
effective antidiabetic drugs, the FDA recommended 
that long-term cardiovascular safety studies for 
antidiabetic drugs be conducted in an established 
time frame following the approval of antidiabetic 
drugs [153].
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